Profile data is unavailable for this security.
About the company
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
- Revenue in USD (TTM)86.73m
- Net income in USD-260.15m
- Incorporated2008
- Employees344.00
- LocationRegenxbio Inc9804 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (240) 552-8181
- Fax+1 (302) 655-5049
- Websitehttps://regenxbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astria Therapeutics Inc | 0.00 | -81.63m | 622.17m | 59.00 | -- | 2.28 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -91.06m | 623.49m | 66.00 | -- | 2.63 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 629.98m | 19.00 | -- | 6.39 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 630.58m | 255.00 | -- | 1.08 | -- | 39.29 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Entrada Therapeutics Inc | 162.87m | 23.49m | 632.94m | 160.00 | 27.29 | 2.14 | 23.63 | 3.89 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Celcuity Inc | 0.00 | -73.45m | 637.79m | 55.00 | -- | 4.18 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Adaptive Biotechnologies Corp | 174.50m | -215.06m | 641.05m | 709.00 | -- | 2.33 | -- | 3.67 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.3238 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Larimar Therapeutics Inc | 0.00 | -45.08m | 643.76m | 42.00 | -- | 2.79 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Applied Therapeutics Inc | -477.00k | -193.56m | 647.90m | 26.00 | -- | 9.63 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
ProKidney Corp | 0.00 | -35.30m | 651.18m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Alumis Inc | 0.00 | -168.82m | 652.21m | 107.00 | -- | -- | -- | -- | -3.26 | -3.26 | 0.00 | 2.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 653.90m | 180.00 | -- | 2.48 | -- | 5.25 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Regenxbio Inc | 86.73m | -260.15m | 654.12m | 344.00 | -- | 1.67 | -- | 7.54 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Arrivent Biopharma Inc | -100.00bn | -100.00bn | 658.15m | 40.00 | -- | 2.07 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
ACELYRIN Inc | 0.00 | -240.16m | 679.33m | 130.00 | -- | 1.05 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
SS Innovations International Inc | 11.22m | -22.75m | 682.96m | 239.00 | -- | 50.46 | -- | 60.87 | -0.1372 | -0.1372 | 0.0698 | 0.0793 | 0.6146 | -- | 2.43 | 46,943.05 | -124.63 | -161.38 | -289.30 | -449.76 | 11.08 | -79.79 | -202.80 | -495.77 | 0.8699 | -57.41 | 0.3901 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.67m | 13.55% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.81m | 9.77% |
Redmile Group LLCas of 31 Mar 2024 | 4.55m | 9.24% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.12m | 6.34% |
JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 1.92m | 3.90% |
JPMorgan Asset Management (UK) Ltd.as of 31 Mar 2024 | 1.72m | 3.50% |
Avidity Partners Management LPas of 31 Mar 2024 | 1.30m | 2.64% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.10m | 2.23% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.07m | 2.17% |
GIC Pte Ltd. (Investment Management)as of 31 Dec 2023 | 1.04m | 2.12% |